Prospect into therapeutic potentials of Moringa oleifera phytocompounds against cancer upsurge: de novo synthesis of test compounds, molecular docking, and ADMET studies

Bulletin of the National Research Centre

Table 3 Pharmacokinetics properties of the potential inhibitors from swissadme server

Compound ID	GI absorption	BBB permeant	Pgp substrate	CYP1A2 inhibitor	CYP2C19 inhibitor	CYP2C9 inhibitor	CYP2D6 inhibitor	CYP3A4 inhibitor
ML2	Low	Yes	No	No	No	No	No	No
ML4	High	Yes	No	Yes	No	No	Yes	No
ML5	High	Yes	No	No	No	No	Yes	No
ML6	High	Yes	No	Yes	No	No	No	No
ML7	Low	No	Yes	No	No	Yes	No	No
ML8	High	Yes	No	Yes	No	No	No	No
ML9	Low	No	Yes	No	No	No	No	No
ML10	Low	No	Yes	No	No	Yes	No	No
ML11	High	No	No	Yes	No	Yes	No	No
ML12	Low	No	No	Yes	No	Yes	No	No
ML13	Low	No	Yes	No	No	No	No	No
ML14	High	No	No	Yes	No	Yes	No	No
ML15	High	No	No	No	No	No	No	Yes
MS1	High	Yes	No	Yes	No	No	No	No
MS2	Low	No	Yes	No	No	No	No	No
MS3	High	No	No	Yes	No	No	No	No
MS4	High	No	No	Yes	No	Yes	No	No
MS5	High	Yes	No	Yes	No	Yes	No	No

GI gastrointestinal, BBB blood–brain barrier, Pgp P-glycoprotein, CYP Cytochrome P